Home › Trial NCT05741164
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
- Trial IDNCT05741164
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorEmory University
- Enrollment37
- Start date2024-09-01
- ConditionsAnatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8 · Metastatic Triple-Negative Breast Carcinoma · Refractory Triple-Negative Breast Carcinoma · Unresectable Triple-Negative Breast Carcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.